Hidradenitis suppurativa (HS) Learning Zone
This Hidradenitis suppurativa (HS) Learning Zone provides:
- Updates in HS from the major congresses
- Expert opinion on current and emerging treatments
- Expert analysis of key publications
- Details of established and in-development treatment options
- The latest on pathophysiology, symptoms and diagnosis, and disease burden
Read updates on investigational treatments, including key results presented at the EHSF 2024 and EADV Congress 2023
Dr Joslyn Kirby explains why it is important for clinicians to keep on top of the latest developments in HS.
This Learning Zone has been developed by EPG Health, with expert insights provided by Dr Joslyn Kirby and Dr Steven Daveluy, both of whom are members of the HS Foundation.
EHSF 2024 - Congress highlights
European Hidradenitis Suppurativa Foundation (EHSF) conference report, with a review of diagnosis, surgery, treatment, guideline and clinical trial updates
EADV 2023 highlights
Recap on key HS highlights from EADV 2023 with expert Professor Falk Bechara
HS Overview
Examine the epidemiology, burden, and diagnosis
HS Treatment
Learn about unmet needs and treatments
HS Guidelines
Clinical practices for hidradenitis suppurativa (HS) are rapidly evolving because of increased attention to HS in recent years and ongoing research on disease pathophysiology and optimal treatments.
Expert opinion
Hear the latest updates on HS from a leading expert
Publication Explainers
Bitesize publication explainer videos exploring the latest big data in HS
Meet the experts
Dr Joslyn Kirby
Dr Kirby, MD, MS, MEd, is a dermatologist and clinician researcher at Penn State Hershey, USA. She earned her medical degree from the University of Virginia, then completed her Dermatology Residency at the University of Pennsylvania. In her clinical and research work, she is interested in acneiform conditions, especially hidradenitis suppurativa, including its effects on people, outcome measurement and pathomechanisms. She is the principal investigator of a number of clinical research trials.
Disclosures: Advisory board member for AbbVie, Incyte, Novartis, and UCB. Consultant for AbbVie, Alumis, DermTech, Guidepoint, Incyte, Insmed, Janssen, Moonlake, Novartis, and UCB. Speaker for AbbVie, Janssen, Novartis, and UCB.
Dr Steven Daveluy
Dr Daveluy, MD, FAAD, is an associate professor and program director at Wayne State University in Detroit, Michigan, USA. He holds special interests in teledermatology, noninvasive skin imaging, skin of color, integrative dermatology, and complex medical dermatology, including hidradenitis suppurativa. He is active on AAD committees, including Performance Measure and DataDerm Oversight.
Disclosures: Speaker/consultant for AbbVie, Novartis, and UCB. Research funds from AbbVie, Pfizer, and UCB.
of interest
are looking at
saved
next event
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Novartis Pharma AG, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.